Pharma poised to cash in on ‘long COVID’ symptomsWhile there’s hope that vaccination campaigns may bring the pandemic under control, “long COVID” side effects may continue Share XPharma poised to cash in on ‘long COVID’ symptomshttps://pharmaphorum.com/news/big-pharma-could-cash-in-on-long/
FDA approves Bayer/Merck & Co heart failure drugBayer and Merck & Co’s heart failure drug vericiguat has been approved by the FDA under the brand Share XFDA approves Bayer/Merck & Co heart failure drughttps://pharmaphorum.com/news/competition-mounts-in-heart-failure-fda-approves-bayer-merck-co-drug/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
NICE backs AZ’s Forxiga for heart failureJust a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE Share XNICE backs AZ’s Forxiga for heart failurehttps://pharmaphorum.com/news/nice-backs-azs-forxiga-for-heart-failure/
Entresto set for big sales hike after FDA panel endorsementNovartis’ Entresto is on course to become the first drug to be approved in the US for a Share XEntresto set for big sales hike after FDA panel endorsementhttps://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement/
AZ’s Q3 results disappoint – but COVID-19 vaccine trial is still on trackAstraZeneca has posted an uninspiring set of quarterly results as it gears up for results from its closely Share XAZ’s Q3 results disappoint – but COVID-19 vaccine trial is still on trackhttps://pharmaphorum.com/news/azs-q3-results-disappoint-but-covid19-vaccine-trial-is-still-on-track/
Boehringer, Yale trial digital tech in heart failurePatients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a Share XBoehringer, Yale trial digital tech in heart failurehttps://pharmaphorum.com/news/boehringer-yale-trial-digital-tech-in-heart-failure/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
